
Loading, please wait...

Loading, please wait...

Recent evidence highlights a critical need for vigilance regarding pediatric IBD kidney impairment in children diagnosed with ulcerative colitis or Crohn’s disease. While extraintestinal manifestations are common, significant kidney impairment (SKI) can lead to irreversible chronic kidney disease if not detected early. Clinicians must balance the necessity of long-term therapy with the risk of idiosyncratic drug reactions.
Researchers have identified that many cases of SKI are linked to 5-aminosalicylic acid (5-ASA) medications, such as mesalamine. Interestingly, studies suggest that 5-ASA-induced nephrotoxicity is often an idiosyncratic reaction rather than a dose-dependent one. Furthermore, inflammatory activity itself may contribute to renal damage through immune-mediated mechanisms. Therefore, baseline screening is mandatory for all pediatric patients entering treatment.
Experts recommend a multi-modal monitoring approach. This includes assessing serum creatinine levels, estimating glomerular filtration rate (eGFR), and performing regular urinalysis for protein-to-creatinine ratios. Additionally, monitoring should occur at diagnosis, three months after starting 5-ASA, and annually thereafter. Consequently, early intervention, such as drug withdrawal or steroid initiation, can significantly improve renal recovery rates.
Clinicians should maintain a high index of suspicion in male patients, as they may have a higher genetic predisposition to 5-ASA-induced interstitial nephritis. Moreover, persistent hematuria or any sustained decrease in eGFR should trigger an immediate referral to a pediatric nephrologist. Coordination between specialties is vital to ensure that growth parameters and kidney health are prioritized throughout the child's development.
Current consensus suggests checking kidney function at baseline, after three months of starting therapy, and then annually for long-term monitoring.
Yes, 5-ASA preparations are the most common cause of drug-induced interstitial nephritis in these patients, though biologics like anti-TNF agents can also rarely be associated with renal issues.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A review of kidney impairment risks in pediatric IBD patients, focusing on 5-ASA monitoring, screening protocols, and specialist practice points....
5 months ago

Following the admission of Union Health Minister JP Nadda to AIIMS Delhi for acute uneasiness, clinical teams utilized diagnostic coronary angiography and inpatient observation. This clinical review outlines acute triage pathways, procedural protocols, post-procedure observation, and long-term risk management.
Today

A multicenter MPOG database study of 289,047 cesarean delivery cases analyzed adherence to obstetric anesthesia best practices. General anesthesia avoidance reached 97.0%, while post-spinal vasopressor infusions (55.4%) and hypothermia prevention (56.7%) showed the lowest compliance, highlighting key targets.
Yesterday

India faces an acute deficit in deceased organ procurement despite rising transplant numbers. With nearly 90,000 patients waiting and deceased donations contributing only 18% of total transplants, healthcare professionals must actively dispel brain death misconceptions and streamline retrieval systems to save lives.
Today

Recent research assesses an automated pipeline for CT-based vertebral finite element analysis, revealing how boundary condition components—especially load-point assignment—impact fracture-load accuracy in spinal biomechanics.
Today

Diabetic kidney disease remains a major cause of renal failure despite renin-angiotensin system blockade. Learn how combining SGLT2 inhibitors, nonsteroidal MRAs, GLP-1 receptor agonists, and novel aldosterone synthase or endothelin inhibitors addresses residual cardiorenal risk.
Today